바이오(Bio)제약산업 발전을 위한 비교법적 연구
Improving Competitiveness in Biopharmaceutical Industry
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Biotechnology has become the driving force of dramatic changes in the innovation process in the pharmaceutical industry. The traditional chemical process of drug discovery and development was replaced by a new biotechnological paradigm. Since 2003, the biopharmaceutical industry including new drug development and diagnostics by virtue of biotechnology was elected as one of Korea's 10 promising Next Generation Technology for Economic Growth. Patents has enabled biotechnology to become a global business in various sectors. Innovations have fueled biotechnology companies' evolution in the world. Government should introduce several mechanism to stimulate and support scientists to protect and exploit their subjective inventions through patenting and licensing. The biopharmaceutical industry is also becoming in need of human resources with managerial business skills. Government should recognize this problem and take adequate actions. Competitive market structure stimulates dynamic efficiency and encourages firms to innovate. Antitrust law should be applied to the anti-competitive business practices such as undue blocking patent, unreasonable defensive patenting especially in biopharmaceutical sector. Public-private collaboration both in the R&D and in the commercialization of subjective invent is needed. Because the exploitation of public research by universities or public research institutes can be constrained by absence or inadequate linkages between public research organizations and industry.
Abstract
Biotechnology has become the driving force of dramatic changes in the innovation process in the pharmaceutical industry. The traditional chemical process of drug discovery and development was replaced by a new biotechnological paradigm. Since 2003, the biopharmaceutical industry including new drug development and diagnostics by virtue of biotechnology was elected as one of Korea's 10 promising Next Generation Technology for Economic Growth. Patents has enabled biotechnology to become a global business in various sectors. Innovations have fueled biotechnology companies' evolution in the world. Government should introduce several mechanism to stimulate and support scientists to protect and exploit their subjective inventions through patenting and licensing. The biopharmaceutical industry is also becoming in need of human resources with managerial business skills. Government should recognize this problem and take adequate actions. Competitive market structure stimulates dynamic efficiency and encourages firms to innovate. Antitrust law should be applied to the anti-competitive business practices such as undue blocking patent, unreasonable defensive patenting especially in biopharmaceutical sector. Public-private collaboration both in the R&D and in the commercialization of subjective invent is needed. Because the exploitation of public research by universities or public research institutes can be constrained by absence or inadequate linkages between public research organizations and industry.
참고문헌 (34)
- 산업연구원, "차세대 성장동력 확충을 위한 바이오산업의 투자로드맵", 3~5 (2007)
- "A Framework for Biotechnology Statistics"[URL]
- OECD, "Innovation in Pharmaceutical Biotechnology: Comparing National Innovation Systems at the Sectoral Level", 22~ (2006)
- K. Bibby, "IMS Global Consulting, Biopharmaceuticals: Moving to Centre Stage, In 2003 BioPeople North American Biotechnology Industry and Suppliers' Guide", pp.3~11 (2003)
- T. Reiss, "Drug Discovery of the Future: The Implications of the Human Genome Project", Trends in Biotechnology, 19, pp.496~499 (2001)
- Lewis M. Branscombe, "Taking Technical Risks: How Innovators, Executives, and Investors Manage High-Tech Risk", 23~ (2001)
- John H. Raubitschek, "Responsibilities Under the Bayh-Dole Act", J. Pat. & Trademark Off. Soc'y, 311 (2005)
- 생명공학육성, 윤리규제 및 유전자변형생물체의 안전성 확보에 관한 비교법제 연구, "이종영", 31~ (2006)
- "National Institutes of Health, Summary of the FY2006 President's Budget"[URL]
- Food Mach, "Walker Process Equip", Food Mach. & Chem. Co, pp.172~ (1965)
- 이종영, "전게서", pp.37~
- A. Gambardella, "Global Competitiveness in Pharmaceuticals, European Commission, DG Enterprise, Brussels", ~ (2000)
- Eurostat data, "Statistics in Focus: High-Tech Industries in the EU" (2003)
- EFPIA, "The Pharmaceutical Industry in Figures" (2007), Brussels
- "European Generic Medicines Association", ~ (2003)
- EFPIA, "The Pharmaceutical Industry in Figures", ~ (2007)
- OECD, "Innovation in Pharmaceutical Biotechnology: Comparing National Innovation Systems at the Sectoral Level", 41~50 (2006)
- Ian Inkster, "The Japanese Industrial Economy 71", ~ (2001)
- "Biotechnology in a Global Economy"[URL]
- National Research Council, "U.S.-Japan Technology Linkages in Biotechnology: Challenges for the 1990s", 6~7 (1992)
- National Research Council, "Intellectual Property Rights and US-Japan Competition in Biotechnology: Report of a Workshop", pp.1~ (1991)
- Kazuyoshi Matsuura, "Institutional Restructuring in the Japanese Economy since 1985, 37 J", ~ (2003)
- Rodney Loeppky, "Encoding Capital: The Political Economy of The Human Genome Project 86", ~ (2005)
- Lita Nelsen, "The Rise of Intellectual Property Protection in the American University, 279 SCIENCE 1460", ~ (1998)
- "일본경제신문, 2005. 5. 24", 일본경제신문, ~ (2005)